Detail

CHEPLAPHARM steps into Therapeutic Area on a large-scale

By acquiring the worldwide rights (except US) for the product VISUDYNE® from the Swiss Novartis Pharma AG, CHEPLAPHARM is now active in the Therapeutic Area Ophthalmology (AMD – age-related macular degeneration) on a global level.

 

By acquiring the worldwide rights (except US) for the product VISUDYNE® from the Swiss Novartis Pharma AG, CHEPLAPHARM is now active in the Therapeutic Area Ophthalmology (AMD – age-related macular degeneration) on a global level.

VISUDYNE®, with its Active Ingredient Verteporfin, is used to treat patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

CHEPLAPHARM is offering its branded products worldwide. VISUDYNE®, an established branded niche product with continuous significance in the therapy of AMD, scores with its Unique Selling Proposition (USP) and a stable market position. Furthermore, the product contribues actively to our ambitious growth strategy by reinforcing CHEPLAPHARM’s International Footprint especially in selected Asian and European countries. Consequently, this acquisition is another step in pursuing our vision to strengthen our position as a global player.

Therefore, we are very excited about having reached an agreement with Novartis Pharma AG about the acquisition of VISUDYNE® - a product that is bringing further scale and diversity to our existing product portfolio.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com

Back